{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.1","upperLimit":"27.3","value":"18.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"OS was defined as the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive. In a clinical trial, measuring the OS is one way to see how well a new treatment works.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Subjects will receive Pralatrexate 25 mg/m2 and Romidepsin 12 mg/m2 intravenously once weekly on days 1 and 15 on a 28-day cycle.","id":"OG000","title":"Phase II"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Overall Survival (OS) of Subjects in Phase 2","type":"SECONDARY","unitOfMeasure":"months"}